ArticleFrontiers in medicine2025

Case Report: Tail-of-the-curve advantage from immune checkpoint inhibitor-anti-VEGF combination therapy: extended survival in a patient with metastatic lung adenocarcinoma.

Junxia Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.